Sucroferric oxyhydroxide (Velphoro®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001228
English
Authors' recommendations:
Sucroferric oxyhydroxide (Velphoro®) is recommended as an option for restricted use within its licensed indication within NHS Wales for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Sucroferric oxyhydroxide (Velphoro®) should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease. Sucroferric oxyhydroxide (Velphoro®) should be restricted as an option for use where non-calcium based phosphate binders are considered appropriate. Sucroferric oxyhydroxide (Velphoro®) is not recommended for use within NHS Wales outside of this subpopulation.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1504
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Peritoneal Dialysis
- Renal Dialysis
- Renal Insufficiency, Chronic
- Drug Therapy, Combination
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.